Germ cell tumors are common malignancies, and chemotherapy with a regimen of bleomycin, etoposide, and cisplatin (BEP) has improved the prognosis for patients with these tumors. However, BEP involves significant myelosuppression, and the safety of pegfilgrastim for the prevention of febrile neutropenia related to myelosuppression has not been well investigated in patients with this tumor type.
Germ cell tumors (GCTs) are common malignancies, and chemotherapy with a regimen of bleomycin, etoposide, and cisplatin (BEP) has improved the prognosis for patients with these tumors. However, BEP involves significant myelosuppression, and the safety of pegfilgrastim for the prevention of febrile neutropenia (FN) related to myelosuppression has not been well investigated in patients with this tumor type.
Researchers from Kanazawa University Hospital in Japan reported in In Vivo on their findings from the treatment of 10 patients with GCTs treated with BEP from 2014 to 2016. All of the patients received BEP every 3 weeks for 2 to 4 cycles. Pegfilgrastim was administered to 5 patients subcutaneously on day 7. Five patients received filgrastim.
The nadir absolute neutrophil count value was lower in those who used filgrastim than in those who used pegfilgrastim (P = .003). FN occurred in 2 cycles using filgrastim and in no cycles using pegfilgrastim. The duration of grade 2 to grade 4 neutropenia in cycles using filgrastim was longer than in those using pegfilgrastim (P = .01). No serious adverse events were observed.
The median number of days until maximum neutrophil count (MNC) in cycles using pegfilgrastim and filgrastim were 8 and 6, respectively. Interestingly, the MNC was recorded most frequently after pegfilgrastim injection in 85% of cycles that used pegfilgrastim. However, the MNC was recorded before filgrastim administration in 50% of cycles. “These results indicate that filgrastim injection may not be efficacious for increasing the neutrophil count in patients under BEP treatment,” wrote the authors.
The study was limited by its small size and by the fact that the median number of filgrastim administrations was 5 (while administration of pegfilgrastim is equivalent to an 11-day course of filgrastim). Larger prospective studies with longer follow-up periods will be needed to confirm the findings in this study, but the authors concluded that using pegfilgrastim with BEP for patients with GCTs may be an effective treatment for neutropenia that also has minimal toxicity.
Reference
Iwamoto H, Izumi K, Natsagdorj A, et al. Effectivness and safety of pegfilgrastim in BEP treatment for patients with germ cell tumor. In Vivo. 2018;32(4):899-903. doi: 10.21873/invivo.112326.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.